Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study Evaluating the Effect of Adding Bortezomib to Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Next Previous
Trial Profile

Phase II Study Evaluating the Effect of Adding Bortezomib to Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Ibrutinib (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Nov 2019 Planned End Date changed from 1 Sep 2029 to 1 Dec 2029.
    • 01 Nov 2019 Planned primary completion date changed from 1 Mar 2022 to 1 Jun 2022.
    • 01 Nov 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Jun 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top